THE РERSONALITY PROFILE OF PATIENTS WITH EARLY MANIFESTATIONS OF PARKINSON'S DISEASE

Cover Page


Cite item

Full Text

Abstract

Background: Mental disorders that sometimes may precede motor dysfunction have an important value in Parkinson's disease, especially at its earlier stages. Personality characteristics of patients with Parkinson's disease have not been studied enough and require a  detailed assessment, because it is a  major factor contributing to treatment efficacy. Aim: To assess personality profiles of patients with early stages of Parkinson's disease and an impact of a dopamine receptor agonist on the personality profile. Materials and methods: We assessed 33 treatment-naïve patients with early symptoms of Parkinson's disease (Hoehn-Yahr stage I and II). The following scales were used before treatment and at 1, 3 and 6 months of treatment with pramipexol: for motor disorders (UPDRS, Unified Parkinson's Disease Rating Scale), depressive disorders (MADRS, Montgomery Asberg Depression Rating Scale) and anxiety disorders (HARS, Hamilton Anxiety Rating Scale), as well as personality profile (MMPI, Minnesota Multiphasic Personality Inventory). Results: The personality profile assessed by MMPI in patients with early stage Parkinson's disease was characterized by highest T scores on scales 2 (pessimism) (74 [64; 86]), 1 (neurotic excess control) (67 [63; 74]), 3  (emotional instability) (64 [56; 70]), 7 (anxiousness) (63 [52; 70]), 8 (autism) (64 [58; 74]), 0  (introversion) (63 [59; 66]). This indicates basic pathopsychological characteristics of patients with early stages of the disease. In particular, their emotional sphere demonstrated anxiety- and depression-related affective disorders. Their personality structure was characterized by dysthymic, anxious, rigid and explosive traits, and susceptibility to hypochondriasis. With a background of a dramatic motivational conflict, frustration of high-level need in self-actualization and recognition due to a chronic disease with motor dysfunction triggered a depressive response type. Pharmacological treatment with pramipexol decreased the neurotic triad at 1 month. However, at subsequent follow-up, there was a gradual shift towards baseline parameters, in spite of a  good clinical efficacy of treatment against motor disorders that indicates a stable sensitive-anxious personality accentuation. Conclusion: Early stages of Parkinson's disease are characterized by a  sensitive-anxious personality structure that is quite stable. This should be taken into account when deciding on a treatment approach to these patients and consideration of potential psychotherapeutic support.

About the authors

R. R. Bogdanov

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: rinatbo@rambler.ru

MD, PhD, Associate Professor, Professor of the Chair of Neurology, Postgraduate Training Faculty

61/2-10 Shchepkina ul., Moscow, 129110

Tel.: +7 (495) 681 56 10

Россия

S. Yu. Borisova

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

Postgraduate Student, Chair of Neurology, Postgraduate Training Faculty

61/2 Shchepkina ul., Moscow, 129110

Россия

S. V. Kotov

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

MD, PhD, Professor; Head of Department of Neurology; Head of Chair of Neurology, Postgraduate Training Faculty

61/2 Shchepkina ul., Moscow, 129110

Россия

O. O. Zavarzina

Russian State Social University

Email: fake@neicon.ru

MD, PhD, Professor; Head of Chair of Special and Clinical Psychology and Inclusive Education

4/1 Vilgelma Pika ul., Moscow, 129226

Россия

References

  1. Катунина ЕА, Бездольный ЮН. Эпидемиология болезни Паркинсона. Журнал неврологии и психиатрии им. C.C. Корсакова. 2013;113(12):81–8.
  2. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6): 525–35. doi: 10.1016/S1474-4422(06)70471-9.
  3. Surmeier DJ, Sulzer D. The pathology roadmap in Parkinson disease. Prion. 2013;7(1):85–91. doi: 10.4161/pri.23582.
  4. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord. 2010;16(2):79–84. doi: 10.1016/j.parkreldis.2009.08.007.
  5. Богданов РР, Мананникова ЕИ, Котов СВ, Богданов АР. Особенности немоторных проявлений на ранних стадиях болезни Паркинсона. Доктор.ру. 2013;5(83):24–8.
  6. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR; NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord. 2011;26(3):399–406. doi: 10.1002/mds.23462.
  7. Богданов РР, Борисова СЮ, Котов СВ. Когнитивные и аффективные расстройства на ранних стадиях болезни Паркинсона. Альманах клинической медицины. 2015;39:90–6.
  8. Yamanishi T, Tachibana H, Oguru M, Matsui K, Toda K, Okuda B, Oka N. Anxiety and depression in patients with Parkinson's disease. Intern Med. 2013;52(5):539–45. doi: http://doi. org/10.2169/internalmedicine.52.8617.
  9. Martínez-Martín P, Damián J. Parkinson disease: Depression and anxiety in Parkinson disease. Nat Rev Neurol. 2010;6(5):243–5. doi: 10.1038/nrneurol.2010.49.
  10. Федорова НВ, Никитина АВ. Депрессия, апатия и ангедония при болезни Паркинсона: механизмы развития немоторных проявлений и подходы к коррекции. Нервные болезни. 2012;(3):22–8.
  11. Blonder LX, Slevin JT. Emotional dysfunction in Parkinson's disease. Behav Neurol. 2011;24(3):201–17. doi: 10.3233/BEN-2011- 0329.
  12. Frisina PG, Borod JC, Foldi NS, Tenenbaum HR. Depression in Parkinson's disease: health risks, etiology, and treatment options. Neuropsychiatr Dis Treat. 2008;4(1):81–91.
  13. Lieberman A. Depression in Parkinson's disease – a review. Acta Neurol Scand. 2006;113(1):1–8. doi: 10.1111/j.1600-0404.2006.00536.x.
  14. Левин ОС. Диагностика и лечение депрессии при болезни Паркинсона. Нервные болезни. 2006;(2):2–8.
  15. Нодель МР, Яхно НН. Нервно-психические нарушения при болезни Паркинсона. Неврология, нейропсихиатрия, психосоматика. 2009;(2):3–8.
  16. Сайко ДЮ. Патопсихологические особенности и органические психические расстройства при болезни Паркинсона. Международный медицинский журнал. 2012;(3):5–9.
  17. McKinlay A, Grace RC, Dalrymple-Alford JC, Anderson T, Fink J, Roger D. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. Parkinsonism Relat Disord. 2008;14(1):37–42. doi: 10.1016/j.parkreldis.2007.05.009.
  18. Leentjens AF, Dujardin K, Marsh L, Richard IH, Starkstein SE, Martinez-Martin P. Anxiety rating scales in Parkinson's disease: a validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale. Mov Disord. 2011;26(3):407– 15. doi: 10.1002/mds.23184.
  19. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–5. doi: 10.1111/j.2044-8341.1959.tb00467.x
  20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9. doi: 10.1192/ bjp.134.4.382.
  21. Собчик ЛН. СМИЛ. Стандартизированный многофакторный метод исследования личности. СПб.: Речь; 2006. 224 с.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2016 Bogdanov R.R., Borisova S.Y., Kotov S.V., Zavarzina O.O.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies